Brecanavir Explained

Brecanavir (INN; codenamed GW640385) is a protease inhibitor which has been studied for the treatment of HIV.[1]

In December 2006, its developer, GlaxoSmithKline discontinued further development because of insurmountable issues regarding formulation.[2]

See also

Notes and References

  1. Hazen R, Harvey R, Ferris R . In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV . Antimicrob. Agents Chemother. . 51 . 9 . 3147–54 . September 2007 . 17620375 . 2043237 . 10.1128/AAC.00401-07 . etal.
  2. GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385) . . 2006-12-18 . 2008-06-11 . dead . https://web.archive.org/web/20081203151032/http://www.gsk.com/media/pressreleases/2006/2006_12_18_GSK945.htm . 2008-12-03 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Brecanavir".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.